Hemasphere

Papers
(The H4-Index of Hemasphere is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
P1462: POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE177
P666: ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR FOLLOW-UP OF ELEVATE-TN113
P550: A PHASE 3, RANDOMIZED TRIAL OF MAGROLIMAB IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY (ENHAN75
P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES62
P805: ALEMTUZUMAB IN RELAPSED SEVERE APLASTIC ANEMIA: LONG-TERM RESULTS OF A PHASE II STUDY61
P1332: PROMISING OUTCOME OF PATIENTS OLDER THAN 70 YEARS WHO UNDERWENT PERIPHERAL BLOOD HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC S57
S256: TABELECLEUCEL FOR EBV-DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL OR SOLID ORGAN TRANSPLANT AFTER FAILURE OF RITUXIMAB ± CHEMOTHERAPY (ALLELE)54
P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB51
P772: LONG-TERM RAVULIZUMAB TREATMENT IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PNH PROVIDES DURABLE CONTROL OF INTRAVASCULAR HEMOLYSIS WITH LOW INCIDENCE OF MAJOR ADVERSE VASCULAR EVENTS AND 39
PB2038: THE POTENTIAL MECHANISM OF TCM TREATMENT OF CHRONIC APLASTIC ANEMIA BASED ON DATA MINING AND NETWORK PHARMACOLOGY37
P1169: ELEVATED CRP AT INFUSION OF AXICABTAGENE CILOLEUCEL PREDICTS HIGH-GRADE CAR-T TOXICITY AND OUTPERFORMS MORE COMPLEX SCORES37
PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA35
S153: MECHANISMS OF TROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TREATMENT WITH PONATINIB AND OTHER TYROSINE KINASE INHIBITORS35
PB2350: SAFETY AND EFFICACY OF HYPODERMOCLYSIS IN PATIENTS WITH HEMATOLOGICAL CANCERS34
Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-bas33
P545: VENETOCLAX (VEN) COMBINED WITH FLAG-IDA IS AN EFFECTIVE REGIMEN FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AND RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)31
P1126: PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)31
EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Waldenström’s Macroglobulinemia31
S272: SAFETY AND PRELIMINARY PHARMACODYNAMIC EFFECTS OF THE FERROPORTIN INHIBITOR VAMIFEPORT (VIT-2763) IN PATIENTS WITH NON-TRANSFUSION-DEPENDENT BETA THALASSEMIA (NTDT): RESULTS FROM A PHASE 2A STUD31
P1365: HUMAN CD117 AS AN IMMUNOTHERAPEUTIC TARGET IN PRECLINICAL MODELS OF ADVANCED SYSTEMIC MASTOCYTOSIS27
S121: MULTIPARAMETER PREDICTION OF MYELOID NEOPLASIA RISK25
The Impact of Sedentary Lifestyle, High-fat Diet, Tobacco Smoke, and Alcohol Intake on the Hematopoietic Stem Cell Niches25
P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW25
P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA24
0.1259400844574